Companies Dominating the Necrotizing Ulcerative Gingivitis (NUG) Treatment Landscape
- Novartis International AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Sanofi S.A.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Abbott Laboratories
- Eli Lilly and Company
- Hindustan Antibiotics Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of necrotizing ulcerative gingivitis treatment is evaluated at USD 1.36 billion.
The necrotizing ulcerative gingivitis treatment market size was over USD 1.13 billion in 2024 and is poised to exceed USD 4.99 billion by 2037, growing at over 12.1% CAGR during the forecast period i.e., between 2025-2037. Growing incidences of oral diseases, and poor diet and dental hygiene will boost the market growth.
North America industry is estimated to hold largest revenue share of 32% by 2037, attributed to increasing prevalence of oral diseases in developed countries, including the US, driven by poor diet, and high cases of diabetes amongst the people.
The major players in the market are Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Eli Lilly and Company, Hindustan Antibiotics Limited
